Secondary Logo

Journal Logo

July/August 2021 - Volume 41 - Issue 4
pp: 359-507

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

Nasser, Azmi; Liranso, Tesfaye; Adewole, Toyin; More

Journal of Clinical Psychopharmacology. 41(4):370-380, July/August 2021.

Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial

Sinkeviciute, Igne; Hugdahl, Kenneth; Bartz-Johannessen, Christoffer; More

Journal of Clinical Psychopharmacology. 41(4):389-396, July/August 2021.

Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus: Exenatide Use Mediates Depressive Scores Through Increased Perceived Stress Levels

Eren-Yazicioglu, Candan Yasemin; Kara, Buket; Sancak, Seda; More

Journal of Clinical Psychopharmacology. 41(4):428-435, July/August 2021.

Duration: 6:39
Journal of Clinical Psychopharmacology July/August 2021, Volume 41, Issue 4;
Obsessive compulsive disorder (OCD) can often be effectively treated with cognitive behavioral therapy or serotonin reuptake inhibitors. About one-third of patients, however, do not receive adequate symptom relief. Jon E. Grant discusses the potential of monoamine oxidase inhibitors (MAOIs) in treatment-resistant OCD. In an article in the journal, Dr. Grant and his coauthors present new data from a case series of nine patients; three had marked improvement on phenelzine and three had some improvement. Large-scale trials are needed to fully assess the benefits and risks of the therapy in this population group.